company background image
688321 logo

Shenzhen Chipscreen Biosciences SHSE:688321 Stock Report

Last Price

CN¥20.95

Market Cap

CN¥8.5b

7D

8.5%

1Y

-7.5%

Updated

20 Oct, 2024

Data

Company Financials +

Shenzhen Chipscreen Biosciences Co., Ltd.

SHSE:688321 Stock Report

Market Cap: CN¥8.5b

688321 Stock Overview

Shenzhen Chipscreen Biosciences Co., Ltd.

688321 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Shenzhen Chipscreen Biosciences Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shenzhen Chipscreen Biosciences
Historical stock prices
Current Share PriceCN¥20.95
52 Week HighCN¥25.25
52 Week LowCN¥12.47
Beta0.59
11 Month Change37.11%
3 Month Change19.37%
1 Year Change-7.51%
33 Year Change-45.66%
5 Year Change-63.69%
Change since IPO-78.02%

Recent News & Updates

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Oct 08
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Aug 21
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Recent updates

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Oct 08
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Aug 21
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Jun 04
We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Apr 24
Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Apr 05
Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Mar 06
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Shareholder Returns

688321CN PharmaceuticalsCN Market
7D8.5%1.6%2.7%
1Y-7.5%0.7%4.6%

Return vs Industry: 688321 underperformed the CN Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: 688321 underperformed the CN Market which returned 4.6% over the past year.

Price Volatility

Is 688321's price volatile compared to industry and market?
688321 volatility
688321 Average Weekly Movement9.8%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.6%
10% most volatile stocks in CN Market11.5%
10% least volatile stocks in CN Market5.3%

Stable Share Price: 688321's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688321's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
20011,187Xian-Ping Luwww.chipscreen.com

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; and CS12192, a highly selective JAK3 kinase inhibitor.

Shenzhen Chipscreen Biosciences Co., Ltd. Fundamentals Summary

How do Shenzhen Chipscreen Biosciences's earnings and revenue compare to its market cap?
688321 fundamental statistics
Market capCN¥8.54b
Earnings (TTM)-CN¥107.86m
Revenue (TTM)CN¥584.27m

14.6x

P/S Ratio

-79.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688321 income statement (TTM)
RevenueCN¥584.27m
Cost of RevenueCN¥70.54m
Gross ProfitCN¥513.72m
Other ExpensesCN¥621.58m
Earnings-CN¥107.86m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 31, 2024

Earnings per share (EPS)-0.26
Gross Margin87.93%
Net Profit Margin-18.46%
Debt/Equity Ratio71.4%

How did 688321 perform over the long term?

See historical performance and comparison